1 – 13 of 13
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Thrombospondin-2 as a diagnostic biomarker for distal cholangiocarcinoma and pancreatic ductal adenocarcinoma
(
- Contribution to journal › Article
- 2020
-
Mark
YAP1 is an independent prognostic marker in pancreatic cancer and associated with extracellular matrix remodeling
(
- Contribution to journal › Article
- 2019
-
Mark
Stromal fibronectin expression in patients with resected pancreatic ductal adenocarcinoma
(
- Contribution to journal › Article
-
Mark
Quantitative proteomics identifies brain acid soluble protein 1 (BASP1) as a prognostic biomarker candidate in pancreatic cancer tissue
(
- Contribution to journal › Article
-
Mark
Galectin 4 is a biomarker for early recurrence and death after surgical resection for pancreatic ductal adenocarcinoma
(
- Contribution to journal › Article
-
Mark
Low P4HA2 and high PRTN3 expression predicts poor survival in patients with pancreatic cancer
(
- Contribution to journal › Article
- 2018
-
Mark
Calcium-activated chloride channel regulator 1 as a prognostic biomarker in pancreatic ductal adenocarcinoma
(
- Contribution to journal › Article
-
Mark
The prognostic role of cancer stem cell markers for long-term outcome after resection of colonic liver metastases
(
- Contribution to journal › Article
-
Mark
Intratumoural leukocyte infiltration is a prognostic indicator among pancreatic cancer patients with type 2 diabetes
(
- Contribution to journal › Article
- 2017
-
Mark
Low MUC4 expression is associated with survival benefit in patients with resectable pancreatic cancer receiving adjuvant gemcitabine
(
- Contribution to journal › Article
-
Mark
Development and In Vitro Characterization of a Gemcitabine-loaded MUC4-targeted Immunoliposome Against Pancreatic Ductal Adenocarcinoma
(
- Contribution to journal › Article
- 2015
-
Mark
The role of SPARC expression in pancreatic cancer progression and patient survival.
(
- Contribution to journal › Article
- 2014
-
Mark
Apicidin Sensitizes Pancreatic Cancer Cells to Gemcitabine by Epigenetically Regulating MUC4 Expression.
(
- Contribution to journal › Article